Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Current Assets (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Current Assets for 3 consecutive years, with $571.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 8.6% to $571.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $571.5 million, a 8.6% increase, with the full-year FY2025 number at $571.5 million, up 8.6% from a year prior.
  • Current Assets was $571.5 million for Q4 2025 at Nuvation Bio, down from $577.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $652.6 million in Q1 2023 to a low of $475.6 million in Q1 2025.
  • A 3-year average of $588.8 million and a median of $597.6 million in 2024 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 8.6% in 2025; the steepest drop was 21.79% in 2025.
  • Nuvation Bio's Current Assets stood at $616.4 million in 2023, then fell by 14.63% to $526.3 million in 2024, then increased by 8.6% to $571.5 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Current Assets are $571.5 million (Q4 2025), $577.5 million (Q3 2025), and $623.2 million (Q2 2025).